VivoSeq
Cardiovascular

Ischemic Stroke

326

Pipeline Programs↗

152

Active Trials↗

105

Companies Involved↗

Ischemic stroke is a highly competitive landscape with 326 programs across 105 companies. The most active players are Suzhou Neuralstem Biopharmaceuticals, Fujian Shengdi Pharmaceutical Co., Ltd., Meridigen Biotech Co., Ltd.. 73 therapies are approved with 75 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

90/100

Pipeline Velocity

75/100

Mech. Concentration

7/100

Completion Rate

77/100

Attrition Rate

11/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

S

Suzhou Neuralstem Biopharmaceuticals

1 program

Phase 1F

Fujian Shengdi Pharmaceutical Co., Ltd.

1 program

Phase 1M

Meridigen Biotech Co., Ltd.

1 program

Phase 1H

Hopstem Biotechnology Inc.

1 program

Phase 1V

Val Adams

1 program

Phase 1F

Fresenius Kabi Oncology Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical50

Magnesium

Spherium Biomed

Revelisa

Federal Center of Cerebrovascular Pathology and Stroke, Russian Federation Ministry of Health

Acetaminophen

Kenvue Brands

Intra-Arterial Cocktail Therapy

Hui-Sheng Chen

Midodrine

Takeda

Phase 120

Verapamil

Val Adams

Magnesium Sulfate

Fresenius Kabi Oncology Ltd.

Sildenafil

Viatris Specialty LLC

Warfarin

Abbott

Mesenchymal Stem Cells

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Phase 2108

Exenatide

AstraZeneca

Natalizumab

Biogen

Epoetin Beta

Roche

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Riboflavin

Cornea and Laser Eye Institute

Phase 375

Tenecteplase

Roche

Alteplase

Roche

Citicoline

University of Texas Southwestern Medical Center

Ticagrelor

AstraZeneca

Xenon

Nobilis Therapeutics Inc.

Approved73

Clopidogrel

Sanofi

Meperidine

Quagen

Cilostazol

Otsuka

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Losartan

Organon and Co

Analysis

Modality Breakdown

87%

Small molecule

349 of 399 classified programs — the dominant modality here.

13%ALL OTHERSProtein / enzyme226%Cell therapy113%Monoclonal antibody92%Peptide82%

Small molecule leads; the ring shows all 399 classified programs, each share of the total. Modality classified for 100% of 431 pipeline programs.

Analysis

Trial Status

532

clinical trials

Completed210 · 39%
Unknown status106 · 20%
Recruiting91 · 17%
Not yet recruiting55 · 10%
Terminated40 · 8%
Withdrawn18 · 3%
Other12 · 2%

Clinical Trials

Trial Activity

532 trials

Endovascular Treatment for eXtra-Large Ischemic Stroke
Recruiting·—·N/A·NCT06388148·286 enrolled
Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke
Recruiting·—·Phase 2·NCT05630586·380 enrolled
Suhexiang Pill for Acute Ischemic Stroke: A Registry Study
Recruiting·—·N/A·NCT05833932·1,000 enrolled
Tenecteplase for Acute Ischemic Stroke Within 4.5 to 6 Hours of Onset (EXIT-BT2)
Recruiting·GGeneral Hospital of Shenyang Military Region·Phase 4·NCT06010628·1,440 enrolled
Clopidogrel Plus Aspirin in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPrime)
Recruiting·UUniversity of Alberta·Phase 2·NCT06638151·200 enrolled
CHinese ischEmic Stroke Beyond 4.5 Hours With TeNecteplase Under Optimized Non-Contrast CT Selection
Recruiting·HHuashan Hospital·Phase 3·NCT06994975·890 enrolled
Registration of Intravenous Thrombolysis for Acute Ischemic Stroke in Southwestern China（IVTIS）
Recruiting·—·N/A·NCT06131385·3,000 enrolled
The Role of Circadian Factors in Regulation of Neuroplasticity in Ischemic Stroke (Interventional)
Recruiting·Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health·Phase 4·NCT05247125·80 enrolled
Effects of Minocycline on Patients With Ischemic Stroke Undergoing Intravenous Thrombectomy
Recruiting·XXijing Hospital·Phase 4·NCT05487417·180 enrolled
Treatment of Acute Ischemic Stroke With Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease
Recruiting·PPeking Union Medical College Hospital·Phase 3·NCT06674460·600 enrolled
Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke
Recruiting·SShanghai Pharmaceuticals Holding Co., Ltd·Phase 2·NCT05686642·300 enrolled
Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)
Recruiting·JJi Xunming,MD,PhD·Phase 3·NCT05965687·1,230 enrolled
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy（RECAST-MT）
Recruiting·—·Phase 3·NCT06559241·2,105 enrolled
Safety and Efficacy of Levofloxacin for Acute Ischemic Stroke
Recruiting·—·N/A·NCT05799326·100 enrolled
Ticagrelor Versus Cilostazol in Ischemic Stroke
Recruiting·KKafrelsheikh University·Phase 3·NCT06561867·900 enrolled
Page 1 of 36

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)